Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30786186 | 0.83 | HRH3 (0.47) | KDM4EL3MBTL1HRH3 | |
| SCHEMBL30786141 | 0.83 | HRH3 (0.47) | KDM4EL3MBTL1HRH3 | |
| SCHEMBL19735731 | 0.80 | KDM4E (0.45) | KDM4EL3MBTL1 | |
| SCHEMBL11664954 | 0.77 | L3MBTL1 (0.51) | KDM4EL3MBTL1 | |
| SCHEMBL30786081 | 0.76 | MCHR1 (0.53) | MCHR1SIGMAR1HRH3 | |
| SCHEMBL15007 | 0.76 | KDM4E (0.61) | KDM4EL3MBTL1HRH3 | |
| SCHEMBL93912 | 0.75 | ALDH1A1 (0.42) | KDM4ESIGMAR1HRH3KCNH2 | |
| SCHEMBL9073783 | 0.75 | RAB9A (0.51) | KDM4EL3MBTL1 | |
| SCHEMBL10503418 | 0.75 | RAB9A (0.51) | KDM4EL3MBTL1 | |
| SCHEMBL11133065 | 0.73 | KCNH2 (0.52) | KDM4EBIRC5SIGMAR1HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049071-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | BEYANG THERAPEUTICS CO LTD (CN) | 2026-02-19 | — | — | US | disclosed |
| EP-4556466-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | Beyang Therapeutics Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025082316-A1 | OPHTHALMIC FORMATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州必扬医药科技有限公司 | 2025-04-24 | — | — | WO | disclosed |
| CN-119604488-A | Protein tyrosine kinase inhibitor and medical application thereof | 苏州必扬医药科技有限公司 | 2025-03-11 | — | — | CN | disclosed |
| WO-2024032584-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | 苏州必扬医药科技有限公司 | 2024-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049071-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | KDR, FLT1, ERBB2 | KDM4E 3216/4885L3MBTL1 607/4885BIRC5 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.